-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This kind of commonly used OTC has been recalled nationwide, and pharmacies have stopped selling it.
This kind of common OTC, national recall
This kind of common OTC, national recallAccording to the Nanguo Morning Post, it was learned from the Drug Administration of Guangxi Zhuang Autonomous Region on March 17 that the compound honeysuckle granules produced by Guangxi Lingyun County Pharmaceutical Co.
The Guangxi Food and Drug Administration noticed that during the supervision and inspection, the bureau found that your company's production quality management was chaotic, the records were untrue, and the production process could not be traced back.
According to the notice, in order to control risks, in accordance with the relevant provisions of the "Drug Administration Law" and "Drug Recall Management Measures", your company is now ordered to suspend the sale and use of compound honeysuckle granules and fully recall them.
Posting documents in many provinces, pharmacies stop selling off the shelves
Posting documents in many provinces, pharmacies stop selling off the shelvesIt is understood that the Guangxi Food and Drug Administration has issued a cooperative recall letter to the Food and Drug Administration of many provinces.
The "Notice on Suspension of Operation and Use of Compound Honeysuckle Granules of Guangxi Lingyun Pharmaceutical Co.
The Sichuan Provincial Food and Drug Administration requires that all municipal (prefecture) market bureaus and inspection branches of the Provincial Food and Drug Administration immediately supervise and urge drug dealers and users within their jurisdictions to take risk control measures such as suspension of sales and use and removal of the above-mentioned products, and assist in doing a good job Relevant work on drug recalls and strengthen risk monitoring of the product.
The "Notice on Assisting the Recall of Compound Honeysuckle Granules from Guangxi Lingyun County Pharmaceutical Co.
The Heilongjiang Provincial Drug Administration issued a document stating that in order to control risks in a timely manner, after a research decision, the municipal (prefectural) market supervision administrations notified the drug retail enterprises in their jurisdictions, and the inspection offices of the provincial bureaus notified the drug wholesale companies in their jurisdictions to immediately remove the product and cooperate The listing holder initiates a product recall.
The Yunnan Provincial Food and Drug Administration also talked about the decision to stop the sales, use and full recall of the compound honeysuckle granules produced by Guangxi Lingyun County Pharmaceutical Co.
The Fujian Provincial Food and Drug Administration requires all drug inspection offices to supervise and urge drug dealers and users within their jurisdiction to immediately suspend the sales and use of compound honeysuckle granules produced by Guangxi Lingyun County Pharmaceutical Co.
Attention pharmacies, the minimum fine for failure to cooperate with the recall is 100,000
Attention pharmacies, the minimum fine for failure to cooperate with the recall is 100,000Article 135 of the new version of the "Drug Administration Law" stipulates that after the drug regulatory department of the people's government of the province, autonomous region, or municipality orders the recall of the drug, if the holder refuses the recall, the value of the drug should be recalled.
If the circumstances are serious, the drug approval documents, drug production license, and drug business license shall be revoked, and the legal representative, the main person in charge, the directly responsible person in charge, and other responsible persons shall be punished with a penalty of not less than 20,000 yuan but not more than 200,000 yuan fine.
If a drug manufacturer, drug distributor, or medical institution refuses to cooperate with the recall, a fine of not less than 100,000 yuan but not more than 500,000 yuan shall be imposed.